MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
11.87
-0.88 (-6.90%)
At close: Jun 5, 2026, 4:00 PM EDT
11.40
-0.47 (-3.96%)
After-hours: Jun 5, 2026, 7:53 PM EDT
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
59.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TScan Therapeutics | 9.14M |
| Seres Therapeutics | 1.15M |
| ImageneBio | 800.00K |
| MediciNova | 596.64K |
| Entera Bio | 42.00K |
| Impact BioMedical | 39.00K |
INKT News
- 2 days ago - MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - GlobeNewsWire
- 8 days ago - MiNK Therapeutics doses first patient in agenT-797 trial - TheFly
- 8 days ago - MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - GlobeNewsWire
- 16 days ago - MiNK Therapeutics reports new data on agenT-797 at ATS 2026 - TheFly
- 16 days ago - MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications - GlobeNewsWire
- 21 days ago - MiNK Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 21 days ago - MiNK Therapeutics Earnings release: Q1 2026 - Filings
- 21 days ago - MiNK Therapeutics Quarterly report: Q1 2026 - Filings